SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Donor minipool NAT screening for HBV, HCV, and HIV: a 2-year experience in a private hospital in Saudi Arabia
16 references·0 citing·33 second hop
Donor minipool NAT screening for HBV, HCV, and HIV: a 2-year experience in a private hospital in Saudi Arabia (2013)Donor minipool NAT screening for HBV, HCV…Screening donated blood for transfusion-transmissible infections, recommendations (2011)Screening donated blood for t…Attitude to blood donation in Saudi Arabia (2011)Attitude to blood donation in…Hepatitis B, hepatitis C and HIV transfusion‐transmitted infections in the 21st century (2010)Hepatitis B, hepatitis C and …Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions (2009)Experience of mandatory nucle…Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors. (2008)Multicenter evaluation of ind…HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas® TaqScreen MPX test in seroconverting donors (2007)HIV-1, HCV and HBV seronegati…Current Risks of Transfusion-Transmitted Agents: A Review (2007)Current Risks of Transfusion-…Hepatitis B virus blood screening: unfinished agendas (2006)Hepatitis B virus blood scree…Assessing the impact of HBV NAT on window period reduction and residual risk (2006)Assessing the impact of HBV N…Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003) (2005)Impact of nucleic acid amplif…Blood safety and nucleic acid testing in Europe (2005)Blood safety and nucleic acid…A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors (2005)A new strategy for estimating…Window‐period human immunodeficiency virus transmission to two recipients by an adolescent blood donor (2004)Window‐period human immunodef…Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia (2004)Prevalence of HBV, HCV, HIV-1…Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population (2002)Current prevalence and incide…Blood transfusion practices in India: results of a national survey. (2000)Blood transfusion practices i…Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing (2004)Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men (2009)Blood Donation, Deferral, and Discrimination: FDA Donor Deferral Policy for Men Who Have Sex With Men (2010)Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus (2014)The Risk of Transfusion-Transmitted Viral Infections (1996)Residual risk of transfusion‐transmitted viral infections in Shenzhen, China, 2001 through 2004 (2007)Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6‐year survey (2008)Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety? (2013)Understanding Canadian student motivations and beliefs about giving blood (2005)Blood donor satisfaction and intention of future donation (2008)The Psychology of Blood Donation: Current Research and Future Directions (2008)Knowledge, Attitudes, and Motivations towards Blood Donation among King Abdulaziz Medical City Population (2014)Public awareness of blood donation in Central Saudi Arabia (2014)Management of blood supply and demand during the COVID-19 pandemic in King Abdullah Hospital, Bisha, Saudi Arabia (2020)Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV‐1 antibody screening (1991)Infectivity of human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion (2009)Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing (2010)Multinational assessment of blood‐borne virus testing and transfusion safety on the African continent (2012)Trends in prevalence, incidence, and residual risk of major transfusion‐transmissible viral infections in United Arab Emirates blood donors: impact of individual‐donation nucleic acid testing, 2004 through 2009 (2012)The prevalence of transfusion-transmitted infections and nucleic acid testing among blood donors in Majmaah, Saudi Arabia (2018)Prevention of transfusion-transmitted infections (2019)Transfusion-transmitted infections (2007)One‐year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations (2009)Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010 (2012)Prevalence and Trend of Major Transfusion-Transmissible Infections among Blood Donors in Western China, 2005 through 2010 (2014)Access to safe blood in low-income and middle-income countries: lessons from India (2017)Dynamic temporary blood facility location-allocation during and post-disaster periods (2017)Need for Nucleic Acid Testing in Countries with High Prevalence of Transfusion-Transmitted Infections (2012)Nucleic acid testing for blood banks: An experience from a tertiary care centre in New Delhi, India (2013)Assessing the global burden of hemorrhage: The global blood supply, deficits, and potential solutions (2021)Bloodborne infections among student voluntary blood donors in Mansoura University, Egypt. (2006)Transfusion transmitted infections – A retrospective analysis from the National Blood Transfusion Service in Eritrea (2011)Association of ABO and Rh Blood Groups to Blood-Borne Infections among Blood Donors in Tehran-Iran. (2014)
this work references cited by second hop

References

  • 2002Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population642 cited
  • 2005A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors426 cited
  • 2007Current Risks of Transfusion-Transmitted Agents: A Review162 cited
  • 2011Screening donated blood for transfusion-transmissible infections, recommendations148 cited
  • 2010Hepatitis B, hepatitis C and HIV transfusion‐transmitted infections in the 21st century144 cited
  • 2011Attitude to blood donation in Saudi Arabia125 cited
  • 2004Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia121 cited
  • 2006Assessing the impact of HBV NAT on window period reduction and residual risk114 cited
  • 2006Hepatitis B virus blood screening: unfinished agendas94 cited
  • 2008Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors.73 cited
  • 2009Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions73 cited
  • 2004Window‐period human immunodeficiency virus transmission to two recipients by an adolescent blood donor73 cited
  • 2005Blood safety and nucleic acid testing in Europe

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

60 cited
  • 2000Blood transfusion practices in India: results of a national survey.39 cited
  • 2005Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003)37 cited
  • 2007HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas® TaqScreen MPX test in seroconverting donors23 cited
  • Cited by

    No citing works inside the corpus for this window.